HealthEquity (HQY) Receives Upgrade: Reasons for the Buy Recommendation
HealthEquity's Upgrade: HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have increased their earnings estimates for HealthEquity, with the Zacks Consensus Estimate rising by 1.6% over the past three months, reflecting an improvement in the company's business outlook.
Market Position: The upgrade places HealthEquity in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price increases due to favorable earnings estimate revisions.
Trade with 70% Backtested Accuracy
Analyst Views on HQY
About HQY
About the author

- Board Expansion: HealthEquity announced the election of William Gassen, CEO of Sanford Health, to its board effective March 26, 2026, increasing the board to 10 members, 8 of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Gassen's leadership experience at Sanford Health will provide HealthEquity with deep insights into healthcare delivery and financing, helping the company better address the challenges faced by consumers, providers, and employers in the healthcare system.
- Focus on Affordability: Gassen emphasized that affordability in healthcare remains a significant challenge for many families and employers, and HealthEquity plays a crucial role in helping people prepare for healthcare expenses, further solidifying the company's market position.
- Educational Background and Professional Experience: Gassen holds a bachelor's degree in criminal justice and a J.D. from the University of South Dakota, and has held several senior leadership roles at Sanford Health, bringing a diverse perspective to the board.
Health Equity Appointment: Bill Gassen has been appointed as the CEO of Sanford Health, focusing on health equity initiatives.
Board of Directors: Gassen will also serve on the Board of Directors, contributing to strategic decisions and governance.
- Revenue and Net Income Growth: HealthEquity reported a 7% year-over-year revenue increase to $334.6 million in Q4, with net income soaring 89% to $49.7 million, indicating strong market performance and enhanced profitability.
- HSA Account Expansion: The company added a record 550,000 Health Savings Accounts (HSAs) in Q4, bringing the total to 17.8 million accounts, reflecting robust growth potential and an expanding customer base in the health savings market.
- Shareholder Returns and Cash Flow: HealthEquity returned over $300 million to shareholders through its share repurchase program, reducing diluted shares by approximately 3%, while generating $457 million in cash flow from operations, enhancing financial flexibility.
- Future Outlook and Guidance: The company expects fiscal 2027 revenue to be between $1.405 billion and $1.415 billion, with GAAP net income projected between $239 million and $246 million, demonstrating confidence in future growth and market opportunities.
- Earnings Highlights: HealthEquity reported a Q4 non-GAAP EPS of $0.95, beating expectations by $0.05, indicating a sustained enhancement in profitability and reflecting robust performance in the health management sector.
- Revenue Growth: Q4 revenue reached $334.6 million, up 7.3% year-over-year, exceeding market expectations by $1.78 million, demonstrating strong growth in customer base and service demand.
- Future Outlook: Management expects revenues for the fiscal year ending January 31, 2027, to be between $1.405 billion and $1.415 billion, slightly below the consensus of $1.41 billion, indicating a cautious approach to future growth.
- Net Income Projections: The anticipated net income ranges from $239 million to $246 million, resulting in diluted earnings per share of $2.78 to $2.85, reflecting the company's efforts in cost control and enhancing profitability.
- Lululemon Earnings Forecast: Lululemon athletica is expected to report an EPS of $4.77 for the quarter ending January 31, 2026, reflecting a 22.31% decrease year-over-year, indicating increased competitive pressure despite consistently beating expectations over the past year.
- DocuSign Growth: DocuSign anticipates an EPS of $0.34, representing a 21.43% increase compared to the same quarter last year, and has beaten expectations every quarter in the past year, highlighting its strong growth potential in the internet software sector.
- HealthEquity Performance: HealthEquity is projected to report an EPS of $0.70, a 27.27% increase year-over-year, and has consistently exceeded expectations in the past year, demonstrating its ongoing growth capability in the medical services industry.
- NextNav Earnings Outlook: NextNav expects an EPS of -$0.13, showing a 48.00% year-over-year improvement, indicating a trend of recovery in the technology services sector despite still reporting negative earnings.










